AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
H.C. Wainwright Raises Price Target on Atai Life Sciences to $15.
ByAinvest
Thursday, Jul 31, 2025 11:48 pm ET1min read
H.C. Wainwright analyst Patrick Trucchio raised the price target on Atai Life Sciences (ATAI) to $15 from $10 while maintaining a Buy rating. Despite missing the primary endpoint in a Phase 2b trial, the firm is bullish on the company due to its focus on its wholly-owned psychedelics pipeline, including BPL-003, which has exceeded expectations.
H.C. Wainwright analyst Patrick Trucchio has raised the price target on Atai Life Sciences (ATAI) to $15 from $10, while maintaining a Buy rating on the stock. This comes after the biotech company's Phase 2b trial for inidascamine (formerly RL-007) in patients with cognitive impairment associated with schizophrenia missed its primary endpoint. Despite this setback, the firm remains optimistic about Atai's future, particularly its wholly-owned psychedelics pipeline, including BPL-003.The firm highlighted BPL-003's compelling Phase 2b data in treatment-resistant depression, which showed statistically significant reductions in the MADRS depression scale as early as Day 2, with most patients becoming discharge-ready within 90 minutes. Based on these results, H.C. Wainwright increased its probability of success for BPL-003 to 85% from 60% previously, while removing RL-007 from its valuation model as Atai prepares to engage regulators in the third quarter of 2025 and initiate a Phase 3 trial in the first half of 2026.
Other analysts have also shown confidence in Atai's prospects. Canaccord Genuity raised its price target to $12, maintaining a Buy rating. Aegis Capital reiterated its Buy rating with an $8 price target. Oppenheimer initiated coverage of Atai with an Outperform rating and a $14 price target. These developments reflect a mix of challenges and opportunities for Atai Life Sciences as it navigates its clinical trials and market evaluations.
References:
[1] https://za.investing.com/news/analyst-ratings/hc-wainwright-raises-atai-life-sciences-stock-price-target-to-15-on-bpl003-potential-93CH-3813453
[2] https://www.investing.com/news/analyst-ratings/hc-wainwright-raises-atai-life-sciences-stock-price-target-to-15-on-bpl003-potential-93CH-4162730
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet